{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:56:51Z","timestamp":1789588611739,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL118018"],"award-info":[{"award-number":["R01 HL118018"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["849569"],"award-info":[{"award-number":["849569"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Heart Association Transformational Project Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Breast cancer treatment results in increased cardiotoxicity risk; a risk-guided approach to cardioprotection has not been fully tested.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This single-center, randomized Phase I trial enrolled patients with Stage I\u2013III breast cancer who planned to receive anthracycline and\/or trastuzumab therapy. An internally validated cardiotoxicity risk score classified participants as low or elevated risk. Elevated risk participants were randomized to receive open-label carvedilol or usual care for 12\u00a0months, beginning at cancer therapy initiation. Study visits occurred at baseline, 3, 6, 9, 12, and 24\u00a0months. Primary outcomes included feasibility, safety, and tolerability. Exploratory outcomes included echocardiography, biologic, and patient-reported measures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 166 eligible patients approached, 68 (41%) agreed to participate and ultimately enrolled. Among these participants (median age 52, 35% Black), 49 were classified as low and 19 elevated risk. Within the elevated risk group, 13 were randomized to carvedilol and 6 usual care. For those randomized to carvedilol, the median maximum dose was 6.25\u00a0mg twice daily, with 93% adherence. Adverse events of interest (grade 3\u2009+\u2009bradycardia, hypotension, or fatigue) occurred in 9% with carvedilol, 13% in usual care, and 4% in low risk groups. One (1.5%) low risk participant experienced cardiac dysfunction. There were no substantial differences in secondary outcomes across groups. The participant withdrawal rate was 7%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This Phase 1 trial demonstrates that a risk-guided strategy can be applied to patients with active cancer. However, additional strategies are necessary to optimize the design and execution of non-treatment intervention trials in patients with active cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>NCT04023110.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10549-025-07636-3","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T12:14:13Z","timestamp":1743768853000},"page":"293-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial"],"prefix":"10.1007","volume":"211","clinical-trial-number":[{"clinical-trial-number":"nct04023110","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Wonyoung","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunga","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anran","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mintzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saveri","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley M.","family":"Knollman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Koropeckyj-Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Messinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congying","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenica N.","family":"Upshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saro H.","family":"Armenian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"1","key":"7636_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"7636_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018802","volume":"10","author":"P Jeyaprakash","year":"2021","unstructured":"Jeyaprakash P, Sangha S, Ellenberger K, Sivapathan S, Pathan F, Negishi K (2021) Cardiotoxic effect of modern anthracycline dosing on left ventricular ejection fraction: a systematic review and meta-analysis of placebo arms from randomized controlled trials. J Am Heart Assoc 10(6):e018802","journal-title":"J Am Heart Assoc"},{"key":"7636_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM (2024) Anthracycline cardiotoxicity in adult cancer patients. JACC CardioOncol 6:655\u2013677","journal-title":"JACC CardioOncol"},{"issue":"1","key":"7636_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jaccao.2022.09.007","volume":"5","author":"S Waliany","year":"2023","unstructured":"Waliany S, Caswell-Jin J, Riaz F, Myall N, Zhu H, Witteles RM, Neal JW (2023) Pharmacovigilance analysis of heart failure associated with anti-HER2 monotherapies and combination regimens for cancer. JACC CardioOncol 5(1):85\u201398","journal-title":"JACC CardioOncol"},{"issue":"3","key":"7636_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jaccao.2023.05.004","volume":"5","author":"PA Henriksen","year":"2023","unstructured":"Henriksen PA, Rankin S, Lang NN (2023) Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity. JACC CardioOncol 5(3):292\u2013297","journal-title":"JACC CardioOncol"},{"issue":"1","key":"7636_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","volume":"4","author":"T Omland","year":"2022","unstructured":"Omland T, Heck SL, Gulati G (2022) The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review. JACC CardioOncol 4(1):19\u201337","journal-title":"JACC CardioOncol"},{"issue":"18","key":"7636_CR7","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"issue":"22","key":"7636_CR8","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","volume":"344","author":"M Packer","year":"2001","unstructured":"Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344(22):1651\u20131658","journal-title":"N Engl J Med"},{"issue":"6","key":"7636_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1388-9842(02)00114-9","volume":"4","author":"A Palazzuoli","year":"2002","unstructured":"Palazzuoli A, Bruni F, Puccetti L, Pastorelli M, Angori P, Pasqui AL, Auteri A (2002) Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 4(6):765\u2013770","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"7636_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0735-1097(20)31285-7","volume":"75","author":"SM Ayub-Ferreira","year":"2020","unstructured":"Ayub-Ferreira SM, Avila M, Brand\u00e3o S, Cruz FD, Wanderley M, Rigaud VOC, Hajjar L, Kalil-Filho R, Cruz CBV, Alves MS et al (2020) Carvedilol for prevention of chemotherapy-induced cardiotoxicity: final results of the prospective, randomized, double-blind, placebo controlled Ceccy trial. J Am Coll Cardiol 75(11):658","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"7636_CR11","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN (2019) Randomized trial of Lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73(22):2859\u20132868","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"7636_CR12","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","volume":"48","author":"N Kalay","year":"2006","unstructured":"Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48(11):2258\u20132262","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"7636_CR13","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S0002-9149(99)00059-4","volume":"83","author":"BD Lowes","year":"1999","unstructured":"Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM (1999) Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 83(8):1201\u20131205","journal-title":"Am J Cardiol"},{"issue":"15","key":"7636_CR14","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1161\/CIRCULATIONAHA.116.023463","volume":"135","author":"HK Narayan","year":"2017","unstructured":"Narayan HK, Finkelman B, French B, Plappert T, Hyman D, Smith AM, Margulies KB, Ky B (2017) Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation 135(15):1397\u20131412","journal-title":"Circulation"},{"issue":"3","key":"7636_CR15","first-page":"269","volume":"16","author":"T Negishi","year":"2023","unstructured":"Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, Shirazi M, Santoro C, Cho G-Y, Popescu BA et al (2023) Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy. JACC 16(3):269\u2013278","journal-title":"JACC"},{"key":"7636_CR16","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jaccao.2024.07.010","volume":"6","author":"D Austin","year":"2024","unstructured":"Austin D, Maier RH, Akhter N, Sayari M, Ogundimu E, Maddox JM, Vahabi S, Humphreys AC, Graham J, Oxenham H et al (2024) Preventing cardiac damage in patients treated for breast cancer and lymphoma. JACC CardioOncol 6:684\u2013696","journal-title":"JACC CardioOncol"},{"issue":"21","key":"7636_CR17","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","volume":"148","author":"PA Henriksen","year":"2023","unstructured":"Henriksen PA, Hall P, MacPherson IR, Joshi SS, Singh T, Maclean M, Lewis S, Rodriguez A, Fletcher A, Everett RJ et al (2023) Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: the cardiac care trial. Circulation 148(21):1680\u20131690","journal-title":"Circulation"},{"key":"7636_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jaccao.2024.07.017","volume":"6","author":"Z Raisi-Estabragh","year":"2024","unstructured":"Raisi-Estabragh Z, Murphy AC, Ramalingam S, Scherrer-Crosbie M, Lopez-Fernandez T, Reynolds KL, Aznar M, Lin AE, Libby P, Cordoba R et al (2024) Cardiovascular considerations before cancer therapy. JACC CardioOncol 6:631\u2013654","journal-title":"JACC CardioOncol"},{"issue":"1","key":"7636_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jaccao.2022.10.010","volume":"5","author":"JA Sparano","year":"2023","unstructured":"Sparano JA, Sahni G (2023) The ESC cardio-oncology guidelines. JACC CardioOncol 5(1):141\u2013144","journal-title":"JACC CardioOncol"},{"issue":"1","key":"7636_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaccao.2022.10.009","volume":"5","author":"DP Leong","year":"2023","unstructured":"Leong DP, Mukherjee SD (2023) The European society of cardiology cardio-oncology guidelines. JACC CardioOncol 5(1):137\u2013140","journal-title":"JACC CardioOncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07636-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07636-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07636-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:16:27Z","timestamp":1744859787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07636-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7636"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07636-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the University of Pennsylvania\u2019s Institutional Review Board and conformed to the Declaration of Helsinki standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}